Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is specifically for treatment-resistant depression, meaning depression symptoms that have not ...

Ketamine remains a fairly new player on the field of depression treatment ... You can only receive esketamine nasal spray, IV therapy, and IM injections at a clinic or hospital.

17 In patients with treatment-resistant depression, reductions in depressive symptoms and in the risk of relapse were observed with esketamine nasal spray as compared with placebo nasal spray when ...

Fast-acting antidepressants can work in hours to help you feel better if you have depression or suicidal thoughts. The FDA in 2019 approved the first, a nasal spray called esketamine for treatment ...

However, Spravato (esketamine) is a patented nasal spray that contains only the S-ketamine molecule. Spravato has been approved by the FDA for adults with treatment-resistant depression since 2019.

In “Esketamine for treatment-resistant depression: A trick of smoke and mirrors?” Gastaldon and colleagues note that two of the three short-term studies used for FDA approval did not find ...

To examine this further, researchers based in China and the U.S. wanted to find out if a single low dose injection of esketamine given just after childbirth might reduce subsequent depression in ...

More information: Antonio Del Casale et al, Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression, JAMA Psychiatry (2025). DOI: 10.1001/jamapsychiatry.2025.0200 ...

A 67-year-old woman with a history of obesity, chronic low back pain, and recurrent episodes of major depression presents ... and ketamine or esketamine therapy) when depressive symptoms are ...

Esketamine targets the glutamate neurotransmitter pathway, offering a novel mechanism for treatment-resistant depression. The treatment is available through a Risk Evaluation and Mitigation ...

Esketamine combined with a serotonin-norepinephrine reuptake inhibitor (SNRI) for treatment-resistant depression (TRD) was linked to significantly lower rates of several adverse outcomes than ...